Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Discovery of a 19F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells
Qiuyan
Shi
a,
Yu
Li
a,
Shaowei
Bo
a,
Xiaofei
Li
a,
Peng
Zhao
b,
Qi
Liu
a,
Zhigang
Yang
a,
Hengjiang
Cong
a,
Hexiang
Deng
a,
Mingnan
Chen
b,
Shizhen
Chen
c,
Xin
Zhou
c,
Hong
Ding
a and
Zhong-Xing
Jiang
*ad
aSchool of Pharmaceutical Sciences and College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430071, China. E-mail: zxjiang@whu.edu.cn
bDepartment of Pharmaceutics and Pharmaceutical Chemistry, School of Pharmacy, University of Utah, Salt Lake City, Utah 84112, USA
cState Key Laboratory for Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences, Wuhan 430071, China
dKey Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
First published on 18th May 2016
Abstract
Correction for ‘Discovery of a 19F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells’ by Qiuyan Shi et al., Chem. Commun., 2016, 52, 5136–5139.
In the original manuscript, the data associated with the MTT assay of salinomycin analogs 5a–z, salinomycin 1 and azide 4 with 4T1 cells constitute IC50 values rather than EC50 values. Therefore, all instances of ‘EC50’ in Table 1 and the corresponding discussion should be corrected to ‘IC50’. Further information about the MTT assay has also been added to the ESI.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2016 |